NewAmsterdam Pharma Company Insiders
| NAMSW Stock | 9.69 0.16 1.68% |
NewAmsterdam Pharma employs about 62 people. The company is managed by 15 executives with a total tenure of roughly 145 years, averaging almost 9.0 years of service per executive, having 4.13 employees per reported executive. Recap of NewAmsterdam Pharma's management performance can provide insight into the venture performance.
NewAmsterdam |
NewAmsterdam Pharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.2927) % which means that it has lost $0.2927 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4737) %, meaning that it generated substantial loss on money invested by shareholders. NewAmsterdam Pharma's management efficiency ratios could be used to measure how well NewAmsterdam Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.54 in 2024. Return On Capital Employed is likely to climb to -0.53 in 2024. At this time, NewAmsterdam Pharma's Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to climb to about 6 M in 2024, whereas Total Assets are likely to drop slightly above 260.6 M in 2024.Common Stock Shares Outstanding is likely to climb to about 86.3 M in 2024
NewAmsterdam Pharma Workforce Comparison
NewAmsterdam Pharma is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 1,243. NewAmsterdam Pharma holds roughly 62.0 in number of employees claiming about 5% of equities under Health Care industry.
NewAmsterdam Pharma Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NewAmsterdam Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on NewAmsterdam Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, NewAmsterdam Pharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Louise Kooij over two weeks ago Disposition of 430015 shares by Louise Kooij of NewAmsterdam Pharma at 10.0 subject to Rule 16b-3 | ||
Lewis William over two months ago Insider Trading | ||
Davidson Michael H. over three months ago Acquisition by Davidson Michael H. of 10399 shares of NewAmsterdam Pharma at 11.17 subject to Rule 16b-3 | ||
Louise Kooij over six months ago Discretionary transaction by Louise Kooij of 213073 shares of NewAmsterdam Pharma subject to Rule 16b-3 |
NewAmsterdam Pharma Notable Stakeholders
A NewAmsterdam Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as NewAmsterdam Pharma often face trade-offs trying to please all of them. NewAmsterdam Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting NewAmsterdam Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| FACC Facp | President CEO | Profile | |
| Louise Kooij | Treasurer, CFO | Profile | |
| Jim Jacobson | Chief Secretary | Profile | |
| Annie Neild | VP Affairs | Profile | |
| FESC MD | Chief Founder | Profile | |
| Marc MD | Chief Officer | Profile | |
| MSc MBA | Chief Officer | Profile | |
| Lina Gugucheva | Chief Officer | Profile | |
| Sheng Cui | Chief Officer | Profile | |
| Douglas Kling | Chief Officer | Profile | |
| Bob Rambo | Executive Marketing | Profile | |
| MBA Jones | Chief Officer | Profile | |
| FACC Facc | President, CEO | Profile | |
| Mayur Somaiya | Chief Officer | Profile | |
| Matthew Philippe | Executive Relations | Profile |
About NewAmsterdam Pharma Management Performance
The success or failure of an entity such as NewAmsterdam Pharma often depends on how effective the management is. NewAmsterdam Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of NewAmsterdam management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the NewAmsterdam management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.51) | (0.54) | |
| Return On Capital Employed | (0.56) | (0.53) | |
| Return On Assets | (0.51) | (0.54) | |
| Return On Equity | (0.61) | (0.58) |
Please note, the imprecision that can be found in NewAmsterdam Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of NewAmsterdam Pharma. Check NewAmsterdam Pharma's Beneish M Score to see the likelihood of NewAmsterdam Pharma's management manipulating its earnings.
NewAmsterdam Pharma Workforce Analysis
Traditionally, organizations such as NewAmsterdam Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare NewAmsterdam Pharma within its industry.NewAmsterdam Pharma Manpower Efficiency
Return on NewAmsterdam Pharma Manpower
| Revenue Per Employee | 205.9K | |
| Revenue Per Executive | 850.8K | |
| Net Loss Per Employee | 2.6M | |
| Net Loss Per Executive | 10.7M | |
| Working Capital Per Employee | 4.8M | |
| Working Capital Per Executive | 19.8M |
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.